Multiple Sclerosis & the Gut Microbiome: Immunity, Dysbiosis, and Research

Overview

Multiple sclerosis (MS) is a chronic autoimmune disorder of the central nervous system (CNS) in which the immune system attacks the protective myelin sheath surrounding nerve fibers, leading to inflammation, demyelination, and progressive neurological disability. Affecting an estimated 2.8 million people worldwide, MS typically presents between the ages of 20 and 40 and is diagnosed approximately three times more frequently in women than in men. While genetic susceptibility -- particularly HLA-DRB1*15:01 -- accounts for a portion of disease risk, environmental factors are believed to play a substantial role in disease initiation and progression.^[1]

The gut microbiome has emerged as one of the most actively investigated environmental factors in MS research. Landmark studies have demonstrated that MS patients harbor a distinct gut microbial composition compared to healthy controls, characterized by depletion of certain beneficial commensals and enrichment of potentially pro-inflammatory taxa. Critically, fecal microbiota transfer experiments have established that these microbial differences are not merely correlational -- transplanting the gut microbiome from MS patients into germ-free mice can trigger spontaneous autoimmune encephalomyelitis, the animal model of MS.^[2]

These findings position the gut as a potential upstream regulator of CNS autoimmunity and have opened promising avenues for microbiome-targeted therapeutic strategies. Understanding the specific mechanisms through which gut bacteria influence MS pathogenesis may lead to complementary interventions that work alongside established disease-modifying therapies. For broader context on how the microbiome drives autoimmune processes, see our guide on autoimmune disorders.

Key Takeaways

• Multiple sclerosis patients consistently show altered gut microbiome composition, with depleted Prevotella species and butyrate-producing bacteria, and enrichment of certain pro-inflammatory taxa
• Fecal microbiota transplantation from MS patients into germ-free mice can induce CNS autoimmunity, providing direct evidence for a causal role of gut bacteria in disease pathogenesis
• Short-chain fatty acids, particularly butyrate and propionate, produced by gut bacteria regulate the Th17/Treg immune balance that is central to MS pathology
• Dietary interventions that increase fiber intake and support beneficial microbial populations may complement conventional MS treatments, though they should not replace disease-modifying therapies
• Disease-modifying therapies for MS may themselves alter gut microbiome composition, suggesting a bidirectional relationship between treatment and microbial ecology

The Microbiome Connection

Gut Dysbiosis in MS Patients

Multiple independent studies have characterized the gut microbiome of MS patients, revealing consistent patterns of dysbiosis. One of the first large-scale investigations found that untreated MS patients showed significant depletion of Prevotella and Butyricimonas genera, alongside enrichment of Methanobrevibacter and Akkermansia.^[1] These shifts were partially normalized in patients receiving disease-modifying therapies, suggesting that both the disease itself and its treatment influence microbial composition.

Pediatric MS patients show similar dysbiotic patterns, with enrichment of members of the Desulfovibrionaceae family and depletion of Lachnospiraceae and Ruminococcaceae -- families that include many key butyrate-producing species.^[3] The consistency of these findings across age groups, geographic regions, and study methodologies strengthens the case for a genuine biological association rather than a confounding artifact. More recently, analysis of progressive MS -- the most disabling form of the disease -- revealed distinct microbial signatures that differed from relapsing-remitting MS, suggesting that microbiome composition may shift as the disease evolves.^[4]

Immune Dysregulation and the Th17/Treg Axis

The central immunological feature of MS is an imbalance between pro-inflammatory Th17 cells and regulatory T cells (Tregs). Th17 cells produce interleukin-17 and other cytokines that drive CNS inflammation and blood-brain barrier breakdown, while Tregs suppress excessive immune responses and maintain self-tolerance. The gut microbiome exerts substantial influence over this balance.

Bacteria isolated from MS patients' stool samples have been shown to directly modulate human T cell responses in vitro. Specifically, Akkermansia muciniphila and Acinetobacter calcoaceticus, which are enriched in MS patients, promoted pro-inflammatory Th1 responses when incubated with human peripheral blood mononuclear cells, while Parabacteroides distasonis, which is depleted in MS, stimulated anti-inflammatory IL-10-producing regulatory T cells.^[5] This provides a mechanistic link between the observed microbial shifts and the immune dysregulation that characterizes MS.

Short-Chain Fatty Acids and CNS Protection

Short-chain fatty acids (SCFAs) -- primarily acetate, propionate, and butyrate -- are produced by bacterial fermentation of dietary fiber and serve as critical mediators of the gut-brain connection. In the context of MS, SCFAs exert several protective effects: they promote Treg differentiation, strengthen the intestinal barrier to prevent systemic immune activation, and may directly support blood-brain barrier integrity.

Propionate has received particular attention in MS research. Dietary supplementation with propionic acid increased Treg frequency and functional suppressive capacity while reducing Th17 cells in both animal models and MS patients.^[6] Butyrate-producing bacteria such as Faecalibacterium prausnitzii are consistently depleted in MS, and reduced SCFA production may contribute to the pro-inflammatory immune environment that drives disease activity. These findings suggest that restoring SCFA-producing capacity in the gut could represent a meaningful therapeutic strategy.

Key Microorganisms

Prevotella histicola (Depleted in MS)

• Impact: Among the most consistently depleted genera in MS patient microbiomes across multiple large cohort studies; its absence is associated with a more pro-inflammatory immune profile
• Function: Produces SCFAs and promotes Treg differentiation; oral administration of Prevotella histicola suppressed experimental autoimmune encephalomyelitis in a humanized mouse model carrying the MS-associated HLA gene, reducing CNS inflammation and demyelination^[7]

Faecalibacterium prausnitzii (Depleted in MS)

• Impact: One of the primary butyrate producers in the human gut; consistently found at reduced abundance in MS patients across relapsing-remitting and progressive disease subtypes
• Function: Produces butyrate that supports Treg differentiation, strengthens both the intestinal and blood-brain barriers, and exerts direct anti-inflammatory effects through inhibition of NF-kB signaling pathways^[1]

Akkermansia muciniphila (Enriched in MS)

• Impact: Paradoxically enriched in MS patients despite its generally beneficial reputation in metabolic health; its overrepresentation may reflect compromised mucus layer dynamics or immune-stimulatory effects in the context of autoimmunity
• Function: Degrades intestinal mucin; in MS, enrichment of Akkermansia correlates with enhanced pro-inflammatory Th1 responses, suggesting its role is context-dependent and may differ between metabolic and autoimmune conditions^[5]

Parabacteroides distasonis (Depleted in MS)

• Impact: Depleted in MS patients; its reduction is associated with loss of immune regulatory capacity in the gut
• Function: Stimulates IL-10-producing regulatory T cells and suppresses pro-inflammatory cytokine production, contributing to maintenance of immune tolerance^[5]

Microbiome-Based Management Strategies

High-Fiber and Anti-Inflammatory Dietary Patterns

Dietary strategies that increase SCFA production through fiber-rich foods may help restore the depleted butyrate-producing bacterial populations observed in MS patients. Propionic acid supplementation specifically has demonstrated immunomodulatory effects in MS, increasing Treg numbers and reducing relapse rates in a clinical study. Mediterranean-style dietary patterns, which emphasize vegetables, legumes, whole grains, and omega-3-rich foods, may support both microbial diversity and anti-inflammatory immune responses. These approaches align with broader evidence linking dietary patterns to MS disease activity.^[6] Evidence Level: Moderate (propionic acid); Preliminary (broader dietary patterns)

Targeted Probiotic Supplementation

Specific bacterial strains have shown promise in preclinical MS models. Prevotella histicola suppressed CNS autoimmunity in a humanized mouse model, reducing both clinical symptoms and demyelinating lesions.^[7] Bifidobacterium longum and Lactobacillus rhamnosus have demonstrated immunomodulatory properties in related autoimmune contexts, promoting Treg development and reducing pro-inflammatory cytokine production. However, large-scale randomized controlled trials in MS populations are still in early stages, and patients should discuss any supplementation with their neurologist. Evidence Level: Preliminary (animal models and small human studies)

Monitoring and Managing Treatment-Related Microbiome Changes

Disease-modifying therapies for MS -- including interferon-beta, glatiramer acetate, and dimethyl fumarate -- have been shown to partially normalize the gut dysbiosis observed in untreated patients.^[1] This raises the possibility that some therapeutic benefit of these drugs may be mediated through microbiome modulation. Patients on these therapies may benefit from dietary and lifestyle strategies that support the favorable microbial shifts induced by treatment, potentially enhancing therapeutic efficacy. Regular monitoring of gut health indicators and discussion with healthcare providers can help optimize this complementary approach. Evidence Level: Preliminary (observational)

Stress Reduction and Sleep Optimization

Psychological stress and sleep disruption are well-established triggers for MS relapses, and both independently alter gut microbiome composition. Chronic stress promotes pro-inflammatory microbial shifts and increases intestinal permeability, potentially amplifying the immune dysregulation that drives MS. Stress management techniques and consistent sleep hygiene may support a more balanced microbial environment. Individuals living with MS often experience depression and chronic fatigue, conditions that are themselves linked to gut dysbiosis, creating compounding effects that integrated management strategies may help address. Evidence Level: Preliminary to Moderate

Future Directions

The intersection of microbiome science and MS research is advancing rapidly. Several clinical trials are currently evaluating fecal microbiota transplantation (FMT) as a therapeutic intervention for MS, building on the preclinical evidence that microbial composition causally influences CNS autoimmunity.^[2] Early results from small pilot studies suggest that FMT may be safe and well-tolerated in MS patients, though efficacy data remain limited.

Propionic acid supplementation represents one of the most promising near-term microbiome-based interventions, given its demonstrated effects on Treg expansion and disease activity in both preclinical and clinical settings.^[6] Larger confirmatory trials are underway to establish optimal dosing, long-term safety, and whether benefits extend across MS subtypes.

Precision microbiome profiling may eventually enable identification of individuals at elevated risk for MS based on their microbial signatures, potentially allowing early intervention before irreversible neurological damage occurs. Longitudinal studies tracking microbiome composition in individuals with clinically isolated syndrome -- often a precursor to MS -- could clarify whether microbial changes precede or follow disease onset.^[4]

It is essential to emphasize that microbiome-targeted strategies should be viewed as complementary to, not replacements for, established disease-modifying therapies. MS remains a serious neurological condition that requires ongoing medical management. Individuals living with MS should consult their neurologist or healthcare team before making changes to their treatment regimen or initiating new dietary or supplement interventions.